Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12in vivo

Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma

(2012) Roniel Cabrera et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity

(2012) Xin Chen et al.   IMMUNOLOGY LETTERS

Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model

(2011) Mengde Cao et al.   LABORATORY INVESTIGATION

Successful Colon Cancer Eradication after Chemoimmunotherapy Is Associated with Profound Phenotypic Change of Intratumoral Myeloid Cells

(2010) J. Medina-Echeverz et al.   JOURNAL OF IMMUNOLOGY

Spontaneous regression of hepatocellular carcinoma: a systematic review

(2009) Susana Oquiñena et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells

(2008) Hetty J. Bontkes et al.   CLINICAL IMMUNOLOGY

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

(2008) Bastian Hoechst et al.   GASTROENTEROLOGY

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma

(2008) Daniel H. Palmer et al.   HEPATOLOGY

CD40ligand‐expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo

(2008) Maria A. Gonzalez‐Carmona et al.   HEPATOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE